Dr. Sol J. Barer is a founder and former Chairman, President, COO, and CEO of Celgene (NASDAQ: CELG). Dr. Barer currently serves as Board Chair for Teva Pharmaceuticals (NYSE: TEVA), NexImmune (NASDAQ: NEXI), Centrexion Therapeutics (NASDAQ: CNTX), and Aevi Genomic Medicine (NASDAQ: GNMX). He is also lead director for Contrafect Corp. (NASDAQ: CFRX) and a member of the Board of Directors for 3DBio Therapeutics.

Dr. Barer is also the Founding Chair of the Hackensack Meridian Health Center for Discovery & Innovation and is a co-founder of Barer & Son Capital, an investment fund focused on capitalizing early-stage breakthrough biotechnology companies. Dr. Barer received his Ph.D. in organic and physical chemistry from Rutgers University and his B.S. in chemistry from Brooklyn College of the City University of New York.